Aminophylline-Dexmedetomidine
PreclinicalSmall molecule
Aminophylline-Dexmedetomidine is one of 17 small molecule programs targeting Bariatric Surgery. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Bariatric Surgery
#DrugCompanyPhaseTrials
1Mounjaro
Eli LillyApproved
Adipex-P
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Topamax
WWim Janssens
Approved
Cyklokapron
JJ Molner
Approved
IC-Green
PProvepharm SAS
Approved
Spravato
WWim Janssens
Approved
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Glucophage
EMD SeronoPhase 3
Gas-X
PPortuguese Oncology Institute, Coimbra
Phase 3
Naltrexone Pill
YYale University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTanta University